Phospho-CSF1R (Tyr708) Antibody

What is the biological significance of CSF1R phosphorylation at Tyr708?

Tyr708 (Tyr706 in mouse) is located in the kinase insert (KI) region of the CSF1R receptor and plays a critical role in receptor signaling. Phosphorylation at this site may significantly influence the binding of PI3 kinase to the activated M-CSF receptor . This phosphorylation event occurs following ligand binding, which induces receptor dimerization and activation through a process of oligomerization and transphosphorylation . The phosphorylated Tyr708 serves as one of several docking sites for SH2-containing signaling proteins that mediate downstream effects on macrophage survival, proliferation, and differentiation .

How should Phospho-CSF1R (Tyr708) antibodies be validated for experimental use?

Proper validation of Phospho-CSF1R (Tyr708) antibodies should include:

• Specificity testing: Using Western blot analysis with extracts from cells known to express CSF1R, such as K-562 cells, as demonstrated in validation data .

• Phospho-specificity verification: Comparing detection in samples with and without phosphatase treatment to confirm the antibody only recognizes the phosphorylated form.

• Immunogen verification: Ensuring the antibody was raised against a synthetic phosphorylated peptide derived specifically from human CSF1R around the Tyr708 site (sequence KKYVR) .

• Cross-reactivity assessment: Testing reactivity across species (human, mouse, rat) if cross-species applications are intended .

• Control experiments: Using appropriate positive controls (e.g., CSF1-stimulated cells) and negative controls (e.g., cells treated with CSF1R inhibitors) to verify signal specificity.

What are the optimal conditions for using Phospho-CSF1R (Tyr708) antibody in Western blotting?

For optimal results, stimulate cells with CSF1/M-CSF before lysis to increase phosphorylation levels .

Which experimental models are most suitable for studying CSF1R Tyr708 phosphorylation?

Most suitable experimental models include:

• Cell lines: K-562 (human chronic myelogenous leukemia) , THP-1 (human monocytic leukemia) , and RAW264.7 (murine macrophage)

• Primary cells: Bone marrow-derived macrophages (BMDMs) polarized into M1-like or M2-like phenotypes

• Animal models: Murine models such as the MC38 colon tumor model for studying CSF1R inhibitors and tumor-associated macrophages

These models are particularly useful because CSF1R is predominantly expressed in mononuclear phagocytes, such as macrophages and monocytes, making them physiologically relevant systems for studying CSF1R signaling .

How can researchers distinguish between CSF1R phosphorylation at Tyr708 and other phosphorylation sites?

To distinguish between different CSF1R phosphorylation sites:

• Site-specific antibodies: Use antibodies that specifically recognize different phosphorylation sites (e.g., Tyr708, Tyr723, Tyr809) in parallel experiments with the same samples .

• Mutational analysis: Generate CSF1R constructs with tyrosine-to-phenylalanine mutations at specific sites to confirm antibody specificity and site function.

• Mass spectrometry: Perform phospho-proteomics analysis to quantitatively assess multiple phosphorylation sites simultaneously.

• Functional correlation: Compare the kinetics of phosphorylation at different sites with downstream signaling events (e.g., Tyr723 with PI3K and PLCγ2 binding, Tyr809 with Shc binding) .

• Inhibitor specificity: Use kinase inhibitors with differential effects on specific phosphorylation sites to determine site-specific roles.

It's important to note that Tyr708 is located in the kinase insert region along with Tyr723, while Tyr809 is in a different domain, potentially leading to distinct functional outcomes when phosphorylated .

What methodologies can be employed to study the relationship between CSF1R Tyr708 phosphorylation and macrophage polarization?

To investigate CSF1R Tyr708 phosphorylation in macrophage polarization:

• Differential polarization assays: Compare phosphorylation levels in M1-like (CSF2/GM-CSF-induced) versus M2-like (CSF1/M-CSF-induced) macrophages using Western blotting with Phospho-CSF1R (Tyr708) antibodies .

• Time-course experiments: Monitor changes in Tyr708 phosphorylation during polarization from M0 to M1 or M2 phenotypes.

• Inhibitor studies: Use CSF1R inhibitors like BPR1R024 to determine how blocking CSF1R signaling affects:

  • M2-like macrophage survival (IC₅₀ = 31 nM)

  • M1-like macrophage growth (IC₅₀ = 5.4 μM)

  • M1/M2 ratio in tumor microenvironments

• Signaling pathway analysis: Correlate Tyr708 phosphorylation with downstream PI3K activation and subsequent effects on macrophage polarization markers.

• Cytokine production assessment: Measure how alterations in Tyr708 phosphorylation affect production of cytokines like TNF-α in response to stimuli such as LPS .

Research has shown that CSF1R inhibitors like BPR1R024 specifically inhibit CSF1-induced M2-like macrophage growth with minimal effect on CSF2-induced M1-like macrophage growth, demonstrating the specificity of CSF1R signaling in maintaining the M2-like phenotype .

How can Phospho-CSF1R (Tyr708) antibodies be utilized in combination with CSF1R inhibitor studies?

Phospho-CSF1R (Tyr708) antibodies can be valuable tools in CSF1R inhibitor studies:

• Target engagement verification: Confirm that CSF1R inhibitors (like BPR1R024, pexidartinib) effectively block Tyr708 phosphorylation using Western blotting .

• Dose-response analysis: Generate dose-response curves showing the relationship between inhibitor concentration and Tyr708 phosphorylation levels. BPR1R024 has demonstrated dose-dependent suppression of CSF1R signaling at concentrations of 50-75 nM in RAW264.7 cells and 1-10 nM in THP-1 cells .

• Temporal dynamics: Assess the kinetics of inhibition and recovery of Tyr708 phosphorylation following treatment with CSF1R inhibitors.

• Selectivity profiling: Compare the effects of different inhibitors on Tyr708 phosphorylation versus other phosphorylation sites to understand inhibitor mechanisms of action.

• In vivo biomarker development: Use Phospho-CSF1R (Tyr708) antibodies to evaluate target inhibition in animal models, such as the MC38 murine colon tumor model, correlating inhibition with tumor growth delay and changes in M1/M2 TAM ratios .

This methodology has been successfully employed to demonstrate that BPR1R024 is a potent CSF1R inhibitor (IC₅₀ = 0.53 nM) with superior target selectivity against a panel of 403 kinases .

How can researchers correlate CSF1R Tyr708 phosphorylation with tumorigenesis and cancer progression?

To investigate the relationship between CSF1R Tyr708 phosphorylation and cancer:

• Tumor sample analysis: Compare Phospho-CSF1R (Tyr708) levels in tumor versus adjacent normal tissues using immunohistochemistry or Western blotting.

• Prognostic correlation: Assess the relationship between Tyr708 phosphorylation levels and clinical outcomes in cancer patients. Activated M-CSF receptor has been shown to predict poor outcomes in advanced epithelial ovarian carcinoma and breast cancer .

• Tumor microenvironment characterization:

  • Quantify M1/M2 macrophage ratios in relation to Tyr708 phosphorylation

  • Correlate with pro-tumorigenic cytokine production

  • Evaluate tumor growth parameters

• Therapeutic intervention studies: Use CSF1R inhibitors to block Tyr708 phosphorylation and monitor effects on:

  • Tumor growth delay (demonstrated in MC38 murine colon tumor model)

  • Reversal of immunosuppressive tumor microenvironment

  • Increased M1/M2 ratio

• Combination therapy assessment: Investigate how CSF1R inhibitors targeting Tyr708 phosphorylation work in conjunction with immune checkpoint inhibitors like avelumab and pembrolizumab, which have shown promise in inducing tumor suppression through multifactorial modulation of immune cells .

Research has demonstrated that oral administration of CSF1R inhibitors like BPR1R024 can delay tumor growth and reverse the immunosuppressive tumor microenvironment with increased M1/M2 ratios, highlighting the potential therapeutic implications of targeting this phosphorylation site .

What are the recommended protocols for immunoprecipitation using Phospho-CSF1R (Tyr708) antibodies?

For successful immunoprecipitation of phosphorylated CSF1R:

• Cell stimulation: Treat cells (e.g., THP-1, RAW264.7, K-562) with CSF1/M-CSF to maximize Tyr708 phosphorylation prior to lysis.

• Lysis conditions:

  • Use a non-denaturing lysis buffer containing phosphatase inhibitors

  • Include 1% NP-40 or Triton X-100, 150 mM NaCl, 50 mM Tris pH 7.5

  • Add protease and phosphatase inhibitor cocktails freshly

• Antibody binding:

  • Use monoclonal antibodies at 1:100 dilution for immunoprecipitation

  • Incubate lysates with antibody overnight at 4°C with gentle rotation

  • Add protein A/G beads and continue incubation for 2-4 hours

• Washing and elution:

  • Wash beads 3-5 times with lysis buffer containing reduced detergent

  • Elute bound proteins with SDS sample buffer (reducing conditions)

  • Heat at 95°C for 5 minutes before SDS-PAGE analysis

• Detection:

  • Perform Western blotting using the same or different Phospho-CSF1R antibody

  • Include total CSF1R antibody analysis in parallel to normalize for expression levels

This protocol has been validated for studying endogenous CSF1R phosphorylation in human cell lines using monoclonal antibodies such as the D5F4Y clone .

How can researchers optimize the detection of CSF1R Tyr708 phosphorylation in tissue samples?

For optimal detection in tissue samples:

• Tissue preparation:

  • Flash-freeze tissues immediately after collection

  • Section tissues at optimal thickness (5-10 μm for IHC)

  • Use phosphatase inhibitors during extraction for biochemical analyses

• Antigen retrieval optimization:

  • Test different pH conditions (citrate buffer pH 6.0 vs. EDTA pH 9.0)

  • Optimize retrieval times and temperatures

  • Consider pressure-cooking methods for improved epitope exposure

• Signal amplification:

  • Employ tyramide signal amplification for immunohistochemistry

  • Use high-sensitivity ECL substrates for Western blotting

  • Consider multiplex fluorescent detection for co-localization studies

• Background reduction:

  • Block with species-specific serum corresponding to secondary antibody

  • Include phospho-peptide blocking controls to verify specificity

  • Optimize antibody concentration to minimize non-specific binding

• Quantification approaches:

  • Use digital image analysis for objective quantification

  • Normalize phospho-signal to total CSF1R expression

  • Include positive control tissues (e.g., lymphoid organs) on each slide

Tissues with high macrophage content (e.g., spleen, liver with Kupffer cells) typically show stronger CSF1R phosphorylation signals and can serve as positive controls.

What strategies can be employed to multiplex Phospho-CSF1R (Tyr708) with other signaling markers?

To effectively multiplex Phospho-CSF1R (Tyr708) with other markers:

• Sequential immunoblotting:

  • Strip and reprobe membranes to detect multiple phospho-proteins

  • Start with the lowest abundance phospho-protein (often Phospho-CSF1R)

  • Document complete stripping between antibody incubations

• Fluorescent Western blotting:

  • Use primary antibodies from different host species (e.g., rabbit anti-Phospho-CSF1R with mouse anti-Phospho-ERK)

  • Apply species-specific secondary antibodies with distinct fluorophores

  • Employ infrared imaging systems for quantitative analysis

• Multi-color flow cytometry:

  • Combine surface staining for CSF1R/CD115 with intracellular phospho-specific staining

  • Use fixation and permeabilization buffers optimized for phospho-epitope preservation

  • Include compensation controls for spectral overlap

• Multiplex immunofluorescence microscopy:

  • Utilize primary antibodies from different species

  • Apply fluorophore-conjugated secondary antibodies with non-overlapping spectra

  • Include markers for macrophage polarization (M1: CD80, iNOS; M2: CD163, CD206)

• Mass cytometry (CyTOF):

  • Label antibodies with distinct metal isotopes

  • Analyze dozens of parameters simultaneously without spectral overlap

  • Particularly useful for comprehensive immune cell profiling in cancer

These multiplexing approaches enable correlation of CSF1R Tyr708 phosphorylation with downstream signaling events such as PI3K/AKT activation and macrophage polarization markers.

What are the considerations for using Phospho-CSF1R (Tyr708) antibodies in cross-species applications?

When using Phospho-CSF1R (Tyr708) antibodies across different species:

• Sequence homology assessment:

  • The phosphorylation site shows high conservation: Tyr708 in human corresponds to Tyr706 in mouse

  • The immunogen sequence (KKYVR) is highly conserved across mammalian species

• Validated cross-reactivity:

  • Some antibodies are validated for human and mouse samples

  • Others may additionally react with rat CSF1R

  • Confirm the specific species reactivity in the product documentation

• Antibody selection strategy:

  • For multi-species studies, select antibodies raised against conserved epitopes

  • Some polyclonal antibodies show broader cross-reactivity than monoclonal antibodies

  • Consider the sequence homology of the entire epitope, not just the phospho-site

• Validation in each species:

  • Perform positive control experiments in each species of interest

  • Use species-specific positive controls (e.g., CSF1-stimulated RAW264.7 cells for mouse, THP-1 for human)

  • Verify molecular weight differences (human: 175 kDa, may vary slightly in other species)

• Species-specific considerations:

  • Optimize lysis conditions for each species/tissue

  • Adjust antibody concentrations based on affinity differences

  • Consider species-specific secondary antibodies to minimize background

While some antibodies are predicted to react based on 100% sequence homology, actual reactivity should be experimentally verified before proceeding with cross-species applications .

How can researchers troubleshoot weak or inconsistent signals when using Phospho-CSF1R (Tyr708) antibodies?

When troubleshooting weak or inconsistent Phospho-CSF1R (Tyr708) signals: